Bristol Myers Squibb Financials

Bristol Myers Stock Summary

Bristol Myers competes with Novartis, Bayer Aktiengesellscha, Astellas Pharma, Roche Holding, and Astellas Pharma. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.

Bristol Myers Key Financial Ratios

Generally speaking, Bristol Myers' financial ratios allow both analysts and investors to convert raw data from Bristol Myers' financial statements into concise, actionable information that can be used to evaluate the performance of Bristol Myers over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Bristol Myers Squibb reports annually and quarterly.

Bristol Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.Bristol Myers Squibb is the top company in revenue category among related companies. It is number one stock in ebitda category among related companies totaling about  0.43  of EBITDA per Revenue. The ratio of Revenue to EBITDA for Bristol Myers Squibb is roughly  2.31 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

If you are still planning to invest in Bristol Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.